CN110740748A - 肿瘤微环境中功能障碍的抗原特异性cd8+t细胞 - Google Patents

肿瘤微环境中功能障碍的抗原特异性cd8+t细胞 Download PDF

Info

Publication number
CN110740748A
CN110740748A CN201880016246.4A CN201880016246A CN110740748A CN 110740748 A CN110740748 A CN 110740748A CN 201880016246 A CN201880016246 A CN 201880016246A CN 110740748 A CN110740748 A CN 110740748A
Authority
CN
China
Prior art keywords
cells
agent
antibody
lag
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880016246.4A
Other languages
English (en)
Chinese (zh)
Inventor
T·加杰斯基
J·威廉姆斯
B·霍顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago filed Critical University of Chicago
Publication of CN110740748A publication Critical patent/CN110740748A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Developmental Biology & Embryology (AREA)
CN201880016246.4A 2017-01-17 2018-01-17 肿瘤微环境中功能障碍的抗原特异性cd8+t细胞 Pending CN110740748A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762447199P 2017-01-17 2017-01-17
US62/447,199 2017-01-17
PCT/US2018/014008 WO2018186924A1 (en) 2017-01-17 2018-01-17 Dysfunctional antigen-specific cd8+ t cells in the tumor microenvironment

Publications (1)

Publication Number Publication Date
CN110740748A true CN110740748A (zh) 2020-01-31

Family

ID=63712313

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880016246.4A Pending CN110740748A (zh) 2017-01-17 2018-01-17 肿瘤微环境中功能障碍的抗原特异性cd8+t细胞

Country Status (6)

Country Link
US (3) US11566077B2 (enExample)
EP (1) EP3570887A4 (enExample)
JP (2) JP2020505342A (enExample)
CN (1) CN110740748A (enExample)
CA (1) CA3049445A1 (enExample)
WO (1) WO2018186924A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202436356A (zh) 2016-10-11 2024-09-16 美商艾吉納斯公司 抗ｌａｇ－３抗體及其使用方法
KR102629972B1 (ko) 2017-04-13 2024-01-29 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
US20220023342A1 (en) * 2018-11-30 2022-01-27 Institut Gustave Roussy Anti-neuropilin-1 and anti-programmed cell death-1 combination therapy for treating cancer
WO2020146772A1 (en) * 2019-01-11 2020-07-16 The Johns Hopkins University Neuritin regulation of t cell anergy and t regulatory cell function
CN109913414A (zh) * 2019-03-21 2019-06-21 吉林省银丰生物工程技术有限公司 肝癌afp特异性人工抗原递呈细胞诱导试剂盒
US20210130438A1 (en) * 2019-10-28 2021-05-06 The Broad Institute, Inc. Pan-cancer t cell exhaustion genes
CA3164578A1 (en) * 2020-01-14 2021-07-22 Scott KANNER Compositions and methods for targeted protein stabilization by redirecting endogenous deubiquitinases
MX2022011409A (es) * 2020-03-17 2022-12-02 Ohio State Innovation Foundation Vesiculas extracelulares de diseño para tratar la excitotoxicidad.
CN111781358A (zh) * 2020-07-13 2020-10-16 张瑜 Xab2蛋白作为卵巢癌预后和/或预测铂类耐药标志物
CN112481375B (zh) * 2020-08-27 2024-02-20 江苏大学 一种胃癌标志物及其应用
CN114350616A (zh) * 2022-01-24 2022-04-15 深圳市先康达生命科学有限公司 一种免疫细胞及其制备方法和应用
CN114814231B (zh) * 2022-03-08 2024-08-27 上海交通大学医学院附属瑞金医院 维甲酸诱导基因i在癌症治疗中的应用
CN114561389A (zh) * 2022-03-15 2022-05-31 南通市肿瘤医院 Vrk1表达抑制剂及其应用
CN115631857B (zh) * 2022-04-01 2023-06-23 洛兮医疗科技(杭州)有限公司 甲状腺癌cd8+t细胞免疫相关基因预后预测模型
CN114720691B (zh) * 2022-05-10 2022-12-09 深圳粒影生物科技有限公司 一种检测生物标志物的试剂盒及其制备方法和应用
CN115449548A (zh) * 2022-09-20 2022-12-09 南京鼓楼医院 Stac2卵丘细胞在评估卵母细胞受精能力中的应用
CN116904309A (zh) * 2023-05-26 2023-10-20 西安天隆科技有限公司 能平衡样本管接收部传热差异的模块、方法及pcr装置
CN117192127B (zh) * 2023-08-18 2024-06-14 肇庆医学高等专科学校 一种hcc治疗靶点的发现方法
CN117590001A (zh) * 2023-11-22 2024-02-23 厦门大学 外泌体tmem176b在制备诊断肿瘤的药物中的用途
CN119120385B (zh) * 2024-11-14 2025-03-14 四川大学华西医院 一种具有长效抑瘤效果的嵌合抗原受体t细胞及其制备方法和用途
CN121046325B (zh) * 2025-11-03 2026-03-17 杭州克斯珀基因技术有限公司 增强肿瘤微环境适应性的cep20敲除型til的制备方法及应用
CN121114292B (zh) * 2025-11-13 2026-01-23 合肥谱佳医学检验实验室有限公司 体外定量检测人血清中四种神经酰胺化合物的检测试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159877A2 (en) * 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
CN102481363A (zh) * 2009-07-14 2012-05-30 旭化成可乐丽医疗株式会社 含有抗癌特异性膜抗原的抗体的癌治疗剂
WO2015119923A1 (en) * 2014-02-04 2015-08-13 Pfizer Inc. Combination of a pd-1 antagonist and a 4-abb agonist for treating cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA877772B (en) 1986-10-23 1988-04-20 Amoco Corporation Target and background capture methods and apparatus for affinity assays
US20070072209A1 (en) 2005-07-07 2007-03-29 Ashlee Moses Methods of treatment and diagnosis of Kaposi's sarcoma (KS) and KS related diseases
WO2008133641A2 (en) * 2006-10-11 2008-11-06 Curagen Corporation Antibodies directed to gpnmb and uses thereof
JP2012025694A (ja) * 2010-07-23 2012-02-09 Asahi Kasei Kuraray Medical Co Ltd 癌治療剤
CN103221428B (zh) * 2010-09-09 2016-02-10 辉瑞公司 4-1bb结合分子
US9297813B2 (en) * 2010-11-11 2016-03-29 Agency For Science, Technology And Research Targeting metabolic enzymes in human cancer
EP2911669B1 (en) 2012-10-26 2024-04-10 The University of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
WO2014144666A2 (en) * 2013-03-15 2014-09-18 The University Of Chicago Methods and compositions related to t-cell activity
CA2963935A1 (en) * 2014-10-08 2016-04-14 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
JP6647315B2 (ja) * 2015-01-09 2020-02-14 イーチュービクス コーポレイション 組み合わせ免疫療法のための方法および組成物
ES2986067T3 (es) * 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
EP3471539A4 (en) 2016-06-03 2020-02-26 The Brigham and Women's Hospital KLRG1 SIGNALING THERAPY

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481363A (zh) * 2009-07-14 2012-05-30 旭化成可乐丽医疗株式会社 含有抗癌特异性膜抗原的抗体的癌治疗剂
WO2011159877A2 (en) * 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
WO2015119923A1 (en) * 2014-02-04 2015-08-13 Pfizer Inc. Combination of a pd-1 antagonist and a 4-abb agonist for treating cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRENDAN HORTON等: "Agonist anti-4-1BB plus neutralizing anti-CTLA-4 or -PD-L1 synergize to promote tumor regression by rescuing dying dysfunctional CD8+ T cells within the tumor microenvironment", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 3, no. 2, pages 10 *
JASON B. WILLIAMS等: "LAG-3 and 4-1BB identify dysfunctional antigen-specific T cells in the tumor microenvironment and combinatorial LAG-3/4-1BB targeting gives synergistic tumor control", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 3, no. 2, pages 328 *

Also Published As

Publication number Publication date
US11566077B2 (en) 2023-01-31
US20200010557A1 (en) 2020-01-09
JP2020505342A (ja) 2020-02-20
WO2018186924A1 (en) 2018-10-11
US20250011452A1 (en) 2025-01-09
US20230416389A1 (en) 2023-12-28
EP3570887A4 (en) 2020-11-25
JP2022184862A (ja) 2022-12-13
CA3049445A1 (en) 2018-10-11
EP3570887A1 (en) 2019-11-27

Similar Documents

Publication Publication Date Title
JP2022184862A (ja) 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞
ES3003809T3 (en) Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides
JP7208010B2 (ja) 癌を標的とするキメラ抗原受容体
CN108780084B (zh) 预测细胞因子释放综合征的生物标志物
JP7510413B2 (ja) Ｂ細胞成熟抗原に特異的なキメラ抗原受容体を使用する処置方法
US11946936B2 (en) Beta-catenin inhibitors in cancer immunotherapy
CN111246862B (zh) 产生基因工程化细胞组合物的方法和相关组合物
US20190185571A1 (en) Methods and compositions for the treatment of cancer combining an anti-smic antibody and immune checkpoint inhibitors
CN110248678A (zh) 调节car-t细胞的方法
CN116162168A (zh) 分子开关调控型嵌合抗原受体细胞和抗体的组合及其应用
CA3180613A1 (en) Treatment of cd30-positive cancer
US20240122992A1 (en) Immunostimulatory bacteria for the treatment of cancer
CN111787930B (zh) 针对癌症特异性抗原对t淋巴细胞的筛选
US20220288225A1 (en) Materials and methods for activating antigen-specific t cell responses
US20230357446A1 (en) Compositions and methods for universal tumor cell killing
Williams et al. c12) United States Patent
Williams et al. c19) United States c12) Patent Application Publication
RU2795984C2 (ru) Изделия и способы для лечения с использованием адоптивной клеточной терапии
HK40122651A (zh) 用於通用肿瘤细胞杀伤的组合物和方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200131

WD01 Invention patent application deemed withdrawn after publication